1. Home
  2. Labeler Index
  3. Marlex Pharmaceuticals Inc
  4. 10135-624
  5. Product Images: Betaxolol

Product Images Betaxolol

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 5 images provide visual information about the product associated with Betaxolol NDC 10135-624 by Marlex Pharmaceuticals Inc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

The following chemical structure of Betaxolol is a β1-selective (cardioselective) adrenergic receptor blocking agent available as 10-mg and 20-mg tablets for oral administration. Betaxolol is chemically described as 2-propanol,1-[4-[2- (cyclopropylmethoxy)ethyl]phenoxy]-3-[(1-methylethyl)amino]-,hydrochloride,(±). - betaxolol tablets usp film coated 01

The following chemical structure of Betaxolol is a β1-selective (cardioselective) adrenergic receptor blocking agent available as 10-mg and 20-mg tablets for oral administration. Betaxolol is chemically described as 2-propanol,1-[4-[2- (cyclopropylmethoxy)ethyl]phenoxy]-3-[(1-methylethyl)amino]-,hydrochloride,(±). - betaxolol tablets usp film coated 01

Betaxolol, like other beta-blockers, has been associated with the development of antinuclear antibodies (ANA) (e.g., lupus erythematosus). In controlled clinical studies, conversion of ANA from negative to positive occurred in 5.3% of the patients treated with betaxolol, 6.3% of the patients treated with atenolol, 4.9% of the patients treated with propranolol, and 3.2% of the patients treated with placebo. Betaxolol adverse events reported with a 2% or greater frequency, and selected events with lower frequency, in U.S. controlled studies are: - betaxolol tablets usp film coated 02

Betaxolol, like other beta-blockers, has been associated with the development of antinuclear antibodies (ANA) (e.g., lupus erythematosus). In controlled clinical studies, conversion of ANA from negative to positive occurred in 5.3% of the patients treated with betaxolol, 6.3% of the patients treated with atenolol, 4.9% of the patients treated with propranolol, and 3.2% of the patients treated with placebo. Betaxolol adverse events reported with a 2% or greater frequency, and selected events with lower frequency, in U.S. controlled studies are: - betaxolol tablets usp film coated 02

In Europe, the placebo-controlled study lasted for 4 weeks, while the comparative studies had a 4-52- week double-blind phase. The following doses were studied: betaxolol 20 and 40 mg once daily and atenolol 100 mg once daily. From European controlled hypertension clinical trials, the following adverse events reported by 2% or more patients and selected events with lower frequency are presented: - betaxolol tablets usp film coated 03

In Europe, the placebo-controlled study lasted for 4 weeks, while the comparative studies had a 4-52- week double-blind phase. The following doses were studied: betaxolol 20 and 40 mg once daily and atenolol 100 mg once daily. From European controlled hypertension clinical trials, the following adverse events reported by 2% or more patients and selected events with lower frequency are presented: - betaxolol tablets usp film coated 03

PRINCIPAL DISPLAY PANELNDC 10135-0623-01MarlexBetaxololTablets, USP10 mg100 film coated TabletsRx Only - betaxolol tablets usp film coated 04

PRINCIPAL DISPLAY PANELNDC 10135-0623-01MarlexBetaxololTablets, USP10 mg100 film coated TabletsRx Only - betaxolol tablets usp film coated 04

PRINCIPAL DISPLAY PANELNDC 10135-0624-01MarlexBetaxololTablets, USP20 mg100 film coated TabletsRx Only - betaxolol tablets usp film coated 05

PRINCIPAL DISPLAY PANELNDC 10135-0624-01MarlexBetaxololTablets, USP20 mg100 film coated TabletsRx Only - betaxolol tablets usp film coated 05